Vincristine 1.6 mg and Prednisolone 80 mg at 17 weeks of pregnancy. She weighed 54 Kg.
Her pregnancy was monitored both clinically and by ultrasonography. Anomaly scan at 18+ weeks revealed no detectable congenital anomaly. She received four more cycles of CHOP chemotherapy at approximately 3 weeks interval at 21 weeks (02/05/08), 24 weeks (27/05/08), 28 weeks (22/06/08) and 32 weeks (26/ 08/08) of pregnancy. During chemotherapy, hematological parameters were normal, except Hb 8.94 gm/dl after the third chemotherapy, it was managed by transfusion of 1 unit of packed cell transfusion. Her liver function was normal except for ALT which was 87 U/L. She had persistent cough and intermittent chest pain during the whole pregnancy period. Her pregnancy was uneventful up to 34 weeks of pregnancy when she had aggravation of burning chest pain which persisted for 3 weeks and was managed conservatively. Echocardiography revealed normal left ventricular function with a 64% ejection fraction at rest. At 37 completed weeks she had lower uterine caesarean section after failed induction and she delivered a healthy female of 2.75 kg with good APGAR score. The baby was screened for haematological parameters, infection and anomaly and was found to be normal by the Paediatric department. Computerized tomograghic scan of the lung ( Figure : 2) was done to evaluate her postchemotherapy state which revealed huge right sided pleural effusion with nearly complete atelectasis of right lung with diffuse hypodense areas suggesting infiltration of the right lung or necrosis after contrast enhancement with patchy parenchymal densities in left lower lung and compression of the mediastinum, trachea and both principal bronchus, with enlarged mediastinal and hilar lymph nodes. Pleurocentesis According to the Ann Arbor Classification of NonHodgkin Lymphoma, NHL Stage IV indicates extensive (diffuse) involvement in one organ or site, with/without NHL in distant lymph nodes. In our case the right lung was diffusely involved by the malignancy along with patchy infiltration of the left lung, suggesting stage IV NHL. The patient had no systemic B symptoms such as fever (greater than 101.5°), drenching night sweats, unexplained weight loss of 10% or more within the last 6 months .In our case there was nodal and primarily extra -nodal involvement (E) 6 . By adding the biologic grade of the disease the staging of our case is Stage IV E NHL intermediate grade(small round cell variety).
The treatment approach should be individualized according to the period of gestation, stage and localization of the disease, the presence or absence of B symptoms (fever, night sweats, and weight loss of more than 10% of the original weight six months prior to first attendance) and the progression of symptoms and signs. 7 Almost all NHL in pregnancy is high grade and most rapid tumour growth is thought to occur in early pregnancy and puerperium especially during lactation. Tumour masses of non-Hodgkin's lymphoma greater than 10 cm in size or mediastinal mass occupying more than half of the transverse thoracic diameter that is bulky disease and raised serum LDH represent poor prognostic signs. 1 Although both radiotherapy and chemotherapy are potentially teratogenic, they can be used safely in some circumstances during pregnancy. A variety of protocols of combination chemotherapy ( CT) has been used for the treatment of NHL in pregnancy in the reported cases with variant outcomes. These are CHOP, CHOP II (cyclophosphamide, vincristin, adriamycin.prednisolone), VACOP-B, CHOP with rituximab and last of all, autologus stem cell transplantation with high-dose CT and ESHAP protocol (Etoposide VP16, Cisplatin, methylprednisolone and ephosphomide) . 7 -11 Radiation with proper shielding can also be given above the diaphragm during the first trimester. Later on it can be used only in areas away from the foetus. 3 Chemotherapy alone cures 30% to 40% of patients with advanced disease of Stage III or Stage IV. Two strategies for treating localized intermediate and highgrade Non-Hodgkin's Lymphoma has emerged without any convincing evidence in favour of either strategy over the recent decades: Chemotherapy alone with CHOP for 6-8 cycles, or a short course of Chemotherapy (usually 3 cycles of CHOP) followed by involved -field Radiotherapy. The presumed advantages of chemotherapy alone are avoidance of long -term complications of radiotherapy and the higher total doses of systemic therapy which increases the potential for eliminating microscopic sites of disease. The possible benefits of short course Chemotherapy followed by Radiotherapy are the reduction in the risk of cardiac toxicity due to the lower total dose of Doxorubicin, the use of two mainly cross-resistant treatments and the advantage of radiation directly to sites of detectable disease. 12 In this case however chest radiotherapy was given after seven cycles of CHOP therapy for progressive disease and she did not suffer from any clinically or echocardiographically proven Doxorubicin -induced cardiac toxicity, may be because of short survival.
Children exposed to high-dose doxorubicincontaining combination chemotherapy in utero (especially during the second and third trimester) have been found to be normal subsequently, with follow-up ranging from several months to 11 years. There are no data regarding long-term effects on children exposed in utero for most of the chemotherapeutic agents used for treatment of NHL. 13 Up to submission of the report of this case the child is in apparent good health.
Conclusion:
Lymphoma is a rare diagnosis in pregnancy. The diagnosis of NHL in pregnancy may be delayed because of reluctance to subject the patient to X-rays and surgical procedures for the non-specific symptoms. Therefore this diagnostic delay should be avoided by all means maintaining a liaison between haematologist, oncologist and obstetrician. Immunohistochemical markers provide prognostic stratification and together with other clinical factors can configure the risk profile for certain groups of patients more accurately , with critical impact on therapeutic decisions. 14 Therefore immunohistochemical evaluations should be considered in every case.
